HDAC inhibitors: A new radiosensitizer for non-small-cell lung cancer

Tumori

Volumn 101, Issue 3, 2015, Pages 257-262

  Zhu, Lucheng ^a   Wu, Kan ^a,b   Ma, Shenglin ^a   Zhang, Shirong ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

DNA damage response; Histone deacetylase inhibitor; Homologous recombination; Non small cell lung cancer; Nonhomologous end joining; Radiosensitizer

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BUTYRIC ACID; CARBOPLATIN; CBHA; DACINOSTAT; ENTINOSTAT; ERLOTINIB; HISTONE DEACETYLASE INHIBITOR; MPT 0 E 028; N 25; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; PLACEBO; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; YCW 1; BENZAMIDE DERIVATIVE; DEPSIPEPTIDE; DNA; DNA BINDING PROTEIN; HR PROTEIN, HUMAN; HYDROXAMIC ACID; INDOLE DERIVATIVE; NHEJ1 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PYRIDINE DERIVATIVE; RADIOSENSITIZING AGENT; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; IONIZING RADIATION; META ANALYSIS; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DNA END JOINING REPAIR; DOWN REGULATION; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; DNA END-JOINING REPAIR; DNA REPAIR ENZYMES; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOWN-REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LUNG NEOPLASMS; PYRIDINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84938277714     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000347     Document Type: Review

References (70)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. Nygren P, Glimelius B; SBU group. Swedish Council on Technology Assessment in Health Care. The Swedish Council on Technology Assessment in Health C are (SBU) report on cancer chemotherapy: project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol. 2001;40(2-3):155-165.
3. Bis choff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat. 2009;19(5): 643-662.
4. Impicciatore G, Sancilio S, Miscia S, Di Pietro R. Nutlins and ionizing radiation in cancer therapy. Curr Pharm Des. 2010;16(12): 1427-1442.
5. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999; 98(3):285-294.
6. Yang X-J, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev. 2003;13(2):143-153.
7. Shahbazian MD, Grunste in M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007; 76(1):75-100.
8. Selvi RB, Kundu TK. Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics. Biotechnol J. 2009;4(3):375-390.
9. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009;107(4):600-608.
10. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834-840.
11. Zhang Y, Fang H, Jiao J, Xu W. The structure and function of histone deacetylases: the target for anti-cancer therapy. Curr Med Chem. 2008;15(27):2840-2849.
12. Wa gner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics. 2010;1:117-136.
13. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 2012;31(5):537-551.
14. Finnin MS, Donigian JR, Pavletich NP. Structure of the histone deacetylase SIRT2. Nat Struct Biol. 2001;8(7):621-625.
15. Kouraklis G, Theocharis S. Histone acetylation and cancer. Acta Oncol. 2003;42(7):792-792.
16. Gregoretti IV, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17-31.
17. Kristensen LS,Nielsen HM,Hansen LL. Epigenetics and cancer treatment Eur J Pharmacol. 2009 625 1-3 131-142.
18. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009;41(1):199-213.
19. Xu WS, Parmigiani RB, Ma rks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37):5541-5552.
20. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010;28(Suppl 1):S3-S20.
21. C hinnaiyan P, Cerna D, Burgan WE, et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res. 2008;14(17):5410-5415.
22. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013;7:47-60.
23. Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res. 2012;116:87-129.
24. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6(6):637-656.
25. Entin-Meer M, Yang X, VandenBerg SR, et al. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncol. 2007;9(2): 82-88.
26. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K. Radiosensitization by SAHA in experimental colorectal carcinoma models: in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Bio l Physics. 2009;74(2):546-552.
27. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cance r Res. 2005;11(13):4912-4922.
28. Mani E, Medina LA, Isaac-Olivé K, Dueñas-González A. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate. Eur J Gyna ecol Oncol. 2014;35(2): 140-142.
29. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol. 1988;35:95-125.
30. Jeggo PA, Geuting V, Löbrich M. The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol. 2011;101(1):7-12.
31. Chen L, Nievera CJ, Lee AY-L, Wu X. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem. 2008;283(12):7713-7720.
32. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-Associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000;14(8):927-939.
33. Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature. 2007;450(7169):509-514.
34. Brenneman MA, Wagener BM, Miller CA, Allen C, Nickoloff JA. XRCC3 controls the fidelity of homologous recombination: roles for XRCC3 in late stages of recombination. Mol Cell. 2002; 10(2):3 87-395.
35. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7(2):263-272.
36. Tibbetts RS, Cortez D, Brumbaugh KM, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev. 2000;14(23):2989-3002.
37. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004;24(2):708-718.
38. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421-429.
39. Furnari B, Rhind N, Russell P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science. 1997; 277(5331):1495-1497.
40. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4(4):511-518.
41. Chapman JR, Taylor MR, Boulto n SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4):497-510.
42. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell. 2002;108(6):781-794.
43. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW. DN A-PK, the DNA-Activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene. 1999;18(20): 3114-3126.
44. Goodarzi AA, Jeggo P, Lobrich M. The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair. 2010;9(12):1273-1282.
45. Rassool FV, Tomkinson AE. Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci. 2010; 67(21): 3699-3710.
46. Samuni Y, Wink DA, Krishna MC, Mitchell JB, Goldstein S. Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide. Free Radic Biol Med. 2014;73:291-298.
47. Chen MC, Chen CH, Wang JC, et al. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKIresistant NSCLC cells. Cell Death Dis. 2013;4(9):e810.
48. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer. 2010;126(3):743-755.
49. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradia ted non-small cell lung cancer. Cancer Res. 2006; 66(23): 11298-11304.
50. Cuneo KC, Fu A, Osusky K, Huamani J, Hallahan DE, Geng L. Histone deacetylase inhibitor NVP-LAQ824 sensitiz es human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs. 2007;18(7):793-800.
51. Zhang Y, Adachi M, Zou H, Hareyama M, Imai K, Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys. 2006;65(3):859-866.
52. Lee JH, Choy ML, Ngo L, Foster SS, Mar ks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA. 2010; 107(33):14639-14644.
53. Zhang F, Zhang T, Teng ZH, Zhan g R, Wang JB, Mei QB. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther. 2009;8(9):823-831.
54. Zhang S, Huang WB, Wu L, Wang LY, Ye LB, Feng BH. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both h uman U251 and H460 cells. Asian Pac J Cancer Prev. 2014; 15(10):4331-4338.
55. Komatsu N, Kawamata N, Takeuchi S, et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small ce ll lung cancer cells. Oncol Rep. 2006;15(1):187-191.
56. Karthik S, Sankar R, Varunkumar K, Ravikumar V. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 2014;68(3):327-334.
57. Seo SK, Jin HO, Woo SH, et al. Histone deace tylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol. 2011;6(8):1313-1319.
58. Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2004; 127(4):1078-1086.
59. Huang WJ,Tang YA,Chen MY,et al. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies Cancer Lett. 2014 346 1, 84-93.
60. Huang WJ, Tang YA, Chen MY, et al. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Lett. 2014;346(1):84-93. 60. Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small ce ll lung cancer cells. Epigenetics. 2012; 7(10):1161-1172.
61. Brazelle W, Kreahling JM, Gemmer J, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010;5(12):e14335.
62. Mukhopadhyay NK, Weisberg E, Gilchrist D, Bueno R, Sugarbaker DJ, Jaklitsch MT. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-smallcell lung cancer. Ann Thorac Surg. 2006;81(3):1034-1042.
63. Reid T, Valone F, Lipera W, et al. Phase II trial of the his tone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004; 45(3):381-386.
64. Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res. 2008;14(1):188-198.
65. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008; 26(5):483-488.
66. Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol. 2009;4(4):522-526.
67. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(1):56-62.
68. Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30(18):2248-2255.
69. Hoang T, Campbell TC, Zhang C, et al. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs. 2014;32(1):195-199.
70. Reguart N, Rosell R, Cardenal F, et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutat ions after erlotinib progression. Lung Cancer. 2014;84(2): 161-167.